Gland Pharma Grows With An Investment Of 400 Crores In Telangana.

Gland Pharma has said they will invest more than Rs 400 crore in the Genome Valley to make their facility better at making Biologicals, Biosimilars, Antibodies, and recombinant Insulin. More than 500 qualified, skilled, and semi-skilled workers, most of whom will come from nearby areas, can get jobs at the expanded facility.

Minister for Information Technology KT Rama Rao said he was happy that Gland Pharma would invest Rs 400 crore to grow in Hyderabad and add 500 jobs in Telangana. The expansion would focus on advanced areas like Biologicals, Biosimilars, Antibodies, and recombinant Insulin. The State is working to build up our capabilities and strengthen our leadership position in these areas.

He said that the growth shows the strength of the life sciences ecosystem in the city and Genome Valley. With an investment of Rs 300 crore, the company opened a biopharmaceutical facility in Genome Valley in February 2022 to make vaccines, biologicals, biosimilars, antibodies, and other medicines. There have already been 200 people hired at the facility. The idea is that the expanded site will follow all national and international rules for making biological products. It will be built according to the GMP guidelines for each product line. Gland Pharma Limited is a pharmaceutical company that focuses on generic injectables. They have given people good healthcare products for more than 40 years. It has eight manufacturing facilities in India can make about 1 billion units of the finished formulation. These include four facilities with 28 production lines for finished formulations and four facilities for Active Pharmaceutical Ingredients (API), including the Genome Valley facility for biopharmaceutical Drug Substances (DS).